ZURICH (Reuters) – Regeneron’s COVID-19 antibody cocktail helped cut the risk of symptomatic infections by 81% among people in households where another member had become ill, according to a statement on Monday from its manufacturing partner, Roche.
“The subcutaneous administration of casirivimab and imdevimab reduced the risk of symptomatic infections by 81% in those who were not infected when they entered the trial,” Roche said.
“In addition, individuals treated with casirivimab and imdevimab who still experienced a symptomatic infection resolved their symptoms on average within one week, compared to three weeks with placebo,” the company said.
(Reporting by John Miller; Editing by Caroline Copley)
